Oppenheimer started coverage on shares of Kadmon (NYSE:KDMN) in a research note issued to investors on Wednesday, June 26th, BenzingaRatingsTable reports. The firm issued an outperform rating and a $6.00 price objective on the stock. Oppenheimer also issued estimates for Kadmon’s Q2 2019 earnings at ($0.16) EPS, Q3 2019 earnings at ($0.16) EPS, Q4 2019 earnings at ($0.17) EPS, FY2019 earnings at ($0.47) EPS, Q1 2020 earnings at ($0.15) EPS, Q2 2020 earnings at ($0.14) EPS, Q3 2020 earnings at ($0.15) EPS, Q4 2020 earnings at ($0.16) EPS, FY2020 earnings at ($0.60) EPS, Q1 2021 earnings at ($0.15) EPS, FY2021 earnings at ($0.58) EPS, FY2022 earnings at ($0.38) EPS and FY2023 earnings at ($0.22) EPS.
A number of other equities research analysts have also commented on the company. Zacks Investment Research lowered HEXO from a hold rating to a sell rating in a research report on Wednesday, May 15th. Citigroup set a $124.00 target price on Eli Lilly And Co and gave the company a hold rating in a research report on Tuesday, February 26th. Finally, HC Wainwright restated a buy rating and issued a $25.00 price objective on shares of Kadmon in a research report on Tuesday, March 12th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Kadmon has a consensus rating of Buy and an average price target of $7.83.
Kadmon stock traded down $0.05 during trading hours on Wednesday, reaching $2.61. The stock had a trading volume of 524,985 shares, compared to its average volume of 932,666. Kadmon has a 52 week low of $1.63 and a 52 week high of $4.39. The company has a market capitalization of $328.88 million, a P/E ratio of -2.53 and a beta of 2.06. The company has a current ratio of 3.89, a quick ratio of 3.85 and a debt-to-equity ratio of 0.60. The stock has a 50 day moving average of $2.05.
Hedge funds have recently made changes to their positions in the company. Amalgamated Bank acquired a new position in shares of Kadmon during the 4th quarter worth approximately $25,000. Metropolitan Life Insurance Co. NY raised its stake in shares of Kadmon by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 26,251 shares of the company’s stock worth $55,000 after buying an additional 20,502 shares during the period. BNP Paribas Arbitrage SA acquired a new position in Kadmon in the 1st quarter valued at $55,000. SG Americas Securities LLC acquired a new position in Kadmon in the 1st quarter valued at $55,000. Finally, Capital Investment Advisors LLC raised its stake in Kadmon by 134.5% in the 2nd quarter. Capital Investment Advisors LLC now owns 28,815 shares of the company’s stock valued at $59,000 after purchasing an additional 16,525 shares during the last quarter. 75.41% of the stock is owned by institutional investors and hedge funds.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
See Also: What is a Special Dividend?
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.